Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200510 | 1.00 | USP30 (0.48) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25417272 | 0.94 | GPR119 (0.46) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31200661 | 0.94 | GPR119 (0.46) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31200782 | 0.89 | GPR119 (0.43) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31200567 | 0.84 | LMNA (0.44) | MEN1KMT2ASMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL31200501 | 0.82 | NAMPT (0.40) | USP30MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL649953 | 0.82 | GPR119 (0.47) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL650888 | 0.82 | GPR119 (0.47) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL653024 | 0.82 | GPR119 (0.47) | USP30GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL928411 | 0.82 | PDE10A (0.48) | GPR119MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225484-B2 | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-01-18 | — | — | US | disclosed |
| US-11225484-B2 | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200369666-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| US-20200369666-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| EP-3665175-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032654-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225484-B2 | Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM4, CHRM3 | USP30 3828/4885GPR119 125/4885MEN1 2108/4885 |
| US-20200369666-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM2, CHRM3 | USP30 3530/4885GPR119 108/4885MEN1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.